UNSPSC 51144104: Amphetamine adipate

This classification denotes a cns stimulant with the molecular formula C9H13N.C6H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z58RH02W4M. The term amphetamine adipate is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule amphetamine adipate under HS 29214600. As of Q4 2014, AMPHETAMINE ADIPATE remains US FDA's Preferred Term for this commodity. Amphetamine adipate bears US NLM identifiers UMLS ID C0982017 and NCI Concept Code C87425. SMILES: CC(CC1CCCCC1)N.C(CCC(=O)O)CC(=O)O.

UNSPSC 51144104 Amphetamine adipate is a Commodity code that captures pharmaceutical active pharmaceutical ingredients (APIs) and finished pharmaceutical products procured by state and local health agencies, correctional systems, and cooperative purchasing alliances. Recent state and local solicitations under this code reflect demand for controlled-substance pharmaceuticals, naloxone-based emergency medications, and generic multi-source drug products distributed through authorized wholesaler networks. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix shows both direct county-level procurement for community health initiatives and aggregated statewide or multi-state contracting vehicles that serve participating jurisdictions across multiple states.

Recent activity spans Florida, Texas, and Minnesota–Oregon cooperative arrangements. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the bid response deadline was July 26, 2023, with electronic submission required and fixed-fee pricing on a two-year term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence request on direct-to-manufacturer prescription programs and therapeutic pharmacy initiatives, signaling future formal procurement once vendor capabilities are assessed. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, with response due March 26, 2026, to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, requiring vendors to work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and to maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, with award effective July 1, 2026.